• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估与20年体重指数相关的心血管疾病人群归因分数;阿提卡研究(2002 - 2022年)

Evaluating population attributable fractions of cardiovascular diseases in relation to 20-year body mass index; the ATTICA study (2002-2022).

作者信息

Damigou Evangelia, Anastasiou Costas, Chrysohoou Christina, Barkas Fotios, Liberopoulos Evangelos, Pitsavos Christos, Tsioufis Costas, Sfikakis Petros P, Panagiotakos Demosthenes

机构信息

Department of Nutrition and Dietetics, School of Health Sciences and Education, Harokopio University, 17676, Athens, Greece.

First Cardiology Clinic, Medical School, National and Kapodistrian University of Athens, 15772, Athens, Greece.

出版信息

Int J Obes (Lond). 2025 May 6. doi: 10.1038/s41366-025-01796-4.

DOI:10.1038/s41366-025-01796-4
PMID:40328923
Abstract

BACKGROUND/OBJECTIVES: The growing prevalence of overweight and obesity globally highlights the need to reconsider the thresholds for defining excess body weight, especially as the health risks associated with weight gain continue to impact population health metrics. This study aimed to evaluate the population attributable fraction (PAF) and prevented fraction for the population (PFP) of CVD cases by body weight trajectories over a 20-year period (2002-2022).

SUBJECTS/METHODS: The studied population-based sample was 1348 individuals (39(10) years old, 48% males), initially free-of-CVD, from the ATTICA cohort study (2002-2022). Combined fatal/non-fatal CVD outcomes were evaluated; body weight and height measurements were performed in 2002, 2012, and 2022 examinations, following standard procedures. Body weight trends, based on cumulative average BMI during 2002-2022, were also calculated. PAF and PFP were computed.

RESULTS

Twenty-nine percent (95%Confidence Interval: 22%, 35%) of CVD cases were prevented by maintaining a normal body weight status during 2002-2022. If increased BMI (>25 kg/m) had been eliminated, 30% (8.7%, 38%) of CVD cases would have been prevented. Three-times more CVD cases would have been prevented if overweight had been managed compared to if obesity had been managed [i.e., 23% (5.1%, 29%) vs 7.2% (1.1%, 9.1%), respectively]. Variations of the PAFs and PFPs were observed by sex, age group, Mediterranean diet adherence, physical activity status, presence of comorbidities, and anxiety trajectories.

CONCLUSIONS

Future public health actions should not neglect to also include people with overweight for the effective management of body weight, which can offer significant long-term benefits for cardiovascular health. A graphical representation of the main study findings on population prevented and attributable fractions by long-term body weight status (n = 1348); the ATTICA study (2002-2022). CVD cardiovascular disease.

摘要

背景/目的:全球超重和肥胖患病率的不断上升凸显了重新审视定义超重的阈值的必要性,尤其是随着与体重增加相关的健康风险继续影响人群健康指标。本研究旨在评估20年期间(2002 - 2022年)按体重轨迹划分的心血管疾病(CVD)病例的人群归因分数(PAF)和人群预防分数(PFP)。

受试者/方法:研究的基于人群的样本来自阿提卡队列研究(2002 - 2022年),共1348人(年龄39(10)岁,48%为男性),最初无CVD。评估了致命/非致命CVD综合结局;按照标准程序在2002年、2012年和2022年检查时测量了体重和身高。还计算了基于2002 - 2022年期间累积平均BMI的体重趋势。计算了PAF和PFP。

结果

在2002 - 2022年期间,通过维持正常体重状态可预防29%(95%置信区间:22%,35%)的CVD病例。如果消除BMI升高(>25 kg/m²),则可预防30%(8.7%,38%)的CVD病例。与管理肥胖相比,管理超重可预防的CVD病例数多出两倍[即分别为23%(5.1%,29%)和7.2%(1.1%,9.1%)]。观察到PAF和PFP因性别、年龄组、地中海饮食依从性、身体活动状况、合并症的存在以及焦虑轨迹而有所不同。

结论

未来的公共卫生行动不应忽视将超重人群纳入体重有效管理,这可为心血管健康带来显著的长期益处。关于长期体重状况对人群预防和归因分数的主要研究结果的图形表示(n = 1348);阿提卡研究(2002 - 2022年)。CVD:心血管疾病

相似文献

1
Evaluating population attributable fractions of cardiovascular diseases in relation to 20-year body mass index; the ATTICA study (2002-2022).评估与20年体重指数相关的心血管疾病人群归因分数;阿提卡研究(2002 - 2022年)
Int J Obes (Lond). 2025 May 6. doi: 10.1038/s41366-025-01796-4.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].[容量与健康结果:来自系统评价和意大利医院数据评估的证据]
Epidemiol Prev. 2013 Mar-Jun;37(2-3 Suppl 2):1-100.
4
Effects of a gluten-reduced or gluten-free diet for the primary prevention of cardiovascular disease.减少或无麸质饮食对心血管疾病一级预防的影响。
Cochrane Database Syst Rev. 2022 Feb 24;2(2):CD013556. doi: 10.1002/14651858.CD013556.pub2.
5
Interventions for weight reduction in obesity to improve survival in women with endometrial cancer.肥胖症减肥干预措施以提高子宫内膜癌女性的生存率。
Cochrane Database Syst Rev. 2023 Mar 27;3(3):CD012513. doi: 10.1002/14651858.CD012513.pub3.
6
Gut microbiome-based interventions for the management of obesity in children and adolescents aged up to 19 years.基于肠道微生物群的干预措施用于管理19岁及以下儿童和青少年的肥胖问题。
Cochrane Database Syst Rev. 2025 Jul 10;7(7):CD015875. doi: 10.1002/14651858.CD015875.
7
Hormonal contraceptives for contraception in overweight or obese women.超重或肥胖女性避孕用激素避孕药
Cochrane Database Syst Rev. 2016 Aug 18;2016(8):CD008452. doi: 10.1002/14651858.CD008452.pub4.
8
Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease.手机短信用于心血管疾病二级预防中的药物依从性。
Cochrane Database Syst Rev. 2024 Mar 27;3(3):CD011851. doi: 10.1002/14651858.CD011851.pub3.
9
Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes.替尔泊肽10毫克和15毫克与司美格鲁肽2.4毫克治疗2型糖尿病患者肥胖和超重的间接比较疗效与安全性
Diabetes Obes Metab. 2025 Jun 19. doi: 10.1111/dom.16508.
10
Interventions to change the behaviour of health professionals and the organisation of care to promote weight reduction in children and adults with overweight or obesity.改变卫生专业人员行为及护理组织方式的干预措施,以促进超重或肥胖儿童及成人减轻体重。
Cochrane Database Syst Rev. 2017 Nov 30;11(11):CD000984. doi: 10.1002/14651858.CD000984.pub3.

本文引用的文献

1
Trends in weight change patterns across life course among US adults, 1988-2018: population-based study.美国成年人一生中体重变化模式的趋势,1988-2018 年:基于人群的研究。
BMC Public Health. 2023 Nov 6;23(1):2168. doi: 10.1186/s12889-023-17137-x.
2
Risk and Population Attributable Fraction of Stroke Subtypes in Japan.日本卒中亚型的风险和人群归因分数。
J Epidemiol. 2024 May 5;34(5):211-217. doi: 10.2188/jea.JE20220364. Epub 2024 Feb 29.
3
Cardiovascular Disease Burden Attributable to High Body Mass Index in Taiwan.台湾地区归因于高体重指数的心血管疾病负担
Acta Cardiol Sin. 2023 Jul;39(4):628-642. doi: 10.6515/ACS.202307_39(4).20221219C.
4
Lifestyle Trajectories Are Associated with Incidence of Cardiovascular Disease: Highlights from the ATTICA Epidemiological Cohort Study (2002-2022).生活方式轨迹与心血管疾病发病率相关:阿提卡流行病学队列研究(2002 - 2022年)亮点
Life (Basel). 2023 May 8;13(5):1142. doi: 10.3390/life13051142.
5
Ultra-processed foods and the development of obesity in adults.超加工食品与成年人肥胖的发展。
Eur J Clin Nutr. 2023 Jun;77(6):619-627. doi: 10.1038/s41430-022-01225-z. Epub 2022 Oct 24.
6
The New 2021 CKD-EPI Equation Without Race in a European Cohort of Renal Transplanted Patients.欧洲肾移植患者队列中不考虑种族因素的2021年新型慢性肾脏病流行病学协作组(CKD-EPI)方程
Transplantation. 2022 Dec 1;106(12):2443-2447. doi: 10.1097/TP.0000000000004234. Epub 2022 Aug 2.
7
Perspective: Obesity-an unexplained epidemic.观点:肥胖——一种无法解释的流行疾病。
Am J Clin Nutr. 2022 Jun 7;115(6):1445-1450. doi: 10.1093/ajcn/nqac075.
8
2021 Dietary Guidance to Improve Cardiovascular Health: A Scientific Statement From the American Heart Association.2021 年改善心血管健康的饮食指导:美国心脏协会的科学声明。
Circulation. 2021 Dec 7;144(23):e472-e487. doi: 10.1161/CIR.0000000000001031. Epub 2021 Nov 2.
9
The global burden of disease attributable to high body mass index in 195 countries and territories, 1990-2017: An analysis of the Global Burden of Disease Study.2019 年全球 195 个国家和地区因超重导致的疾病负担:基于全球疾病负担研究的分析。
PLoS Med. 2020 Jul 28;17(7):e1003198. doi: 10.1371/journal.pmed.1003198. eCollection 2020 Jul.
10
Use of the prevented fraction for the population to determine deaths averted by existing prevalence of physical activity: a descriptive study.利用人群的预防部分来确定因现有体力活动流行率而避免的死亡人数:一项描述性研究。
Lancet Glob Health. 2020 Jul;8(7):e920-e930. doi: 10.1016/S2214-109X(20)30211-4.